NYSEAMERICAN:AZTR Azitra (AZTR) Stock Price, News & Analysis $0.13 0.00 (-3.46%) As of 02:22 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesSEC FilingsBuy This Stock About Azitra Stock (NYSEAMERICAN:AZTR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Azitra alerts:Sign Up Key Stats Today's Range$0.13▼$0.1450-Day Range$0.13▼$0.2452-Week Range$0.10▼$1.60Volume360,944 shsAverage Volume10.94 million shsMarket Capitalization$2.12 millionP/E RatioN/ADividend YieldN/APrice Target$4.00Consensus RatingBuy Company Overview Azitra Inc is a clinical-stage biopharmaceutical company focused on developing live bacterial therapies for dermatological conditions. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary ActoBiotic platform to formulate topical treatments that aim to modulate the skin’s native microbial ecosystem. The company’s lead investigational therapies are being evaluated in early-phase clinical studies for inflammatory skin disorders, including atopic dermatitis and other conditions characterized by microbial imbalance. By delivering live commensal organisms directly to affected skin regions, Azitra seeks to restore healthy barrier function and reduce inflammation without relying on conventional small-molecule or biologic drug approaches. Founded in 2018, Azitra is traded on the NYSE American under the symbol AZTR. Its research and development operations combine microbiology, formulation science and translational dermatology, and the company’s clinical trials are conducted primarily in North America. Azitra has pursued collaborations with academic and medical centers to support its pipeline advancement. Azitra’s leadership team brings together expertise in microbiome research, dermatology and pharmaceutical development, guiding the company toward regulatory milestones and strategic partnerships. With a mission to harness the therapeutic potential of the skin microbiome, Azitra aims to offer novel, targeted treatments for patients with chronic skin diseases.AI Generated. May Contain Errors. Read More Azitra Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreAZTR MarketRank™: Azitra scored higher than 44% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAzitra has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.Upside PotentialAzitra has a consensus price target of $4.00, representing about 2,953.4% upside from its current price of $0.13.Amount of Analyst CoverageAzitra has received no research coverage in the past 90 days.Read more about Azitra's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Azitra are expected to grow in the coming year, from ($0.25) to ($0.08) per share.Price to Book Value per Share RatioAzitra has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Azitra's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.72% of the float of Azitra has been sold short.Short Interest Ratio / Days to CoverAzitra has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Azitra has recently increased by 30.21%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAzitra does not currently pay a dividend.Dividend GrowthAzitra does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 1 people have searched for AZTR on MarketBeat in the last 30 days. This is a decrease of -93% compared to the previous 30 days.MarketBeat Follows8 people have added Azitra to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Azitra insiders have not sold or bought any company stock.Percentage Held by Insiders0.28% of the stock of Azitra is held by insiders.Percentage Held by Institutions11.16% of the stock of Azitra is held by institutions.Read more about Azitra's insider trading history. Receive AZTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Azitra and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AZTR Stock News HeadlinesAzitra, Inc. Announces Breakthough Repeat Dose and Anti-Wrinkle Ex Vivo Results for ATR-COSF Program, Demonstrating Increased Distribution and ElasticityJuly 15, 2026 | prnewswire.comAzitra Expands Authorized Shares Following Stockholder ApprovalsJune 18, 2026 | theglobeandmail.comNEW LAW: Congress Approves Setup For Digital Dollar?On July 17th, the House passed the GENIUS Act - and at least one prominent Trump ally is raising alarms. Rep. Marjorie Taylor Greene claims the bill contains 'the entire setup, groundwork and infrastructure to move from cash to digital currency.' If the legislation becomes law, the implications for how Americans store and control their money could be significant. There may be a limited window to act before it takes effect.July 22 at 1:00 AM | Goldco Direct, LLC (Ad)Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and BeyondJune 17, 2026 | prnewswire.comAzitra, Inc. to Present at 2026 BIO International ConventionJune 16, 2026 | prnewswire.comAzitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened MeetingJune 4, 2026 | prnewswire.comAzitra Announces Intention to Adjourn Annual Meeting and Reconvene Annual MeetingMay 27, 2026 | prnewswire.comAZTR: More background on cosmetic opportunityMay 22, 2026 | msn.comSee More Headlines AZTR Stock Analysis - Frequently Asked Questions How have AZTR shares performed this year? Azitra's stock was trading at $0.2648 at the start of the year. Since then, AZTR shares have decreased by 50.5% and is now trading at $0.1310. How were Azitra's earnings last quarter? Azitra, Inc. (NYSEAMERICAN:AZTR) posted its quarterly earnings data on Wednesday, May, 13th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by $0.24. When did Azitra's stock split? Azitra's stock reverse split before market open on Friday, August 22nd 2025.The 100-666 reverse split was announced on Monday, August 11th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 21st 2025. An investor that had 100 shares of stock prior to the reverse split would have 15 shares after the split. How do I buy shares of Azitra? Shares of AZTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Azitra own? Based on aggregate information from My MarketBeat watchlists, some other companies that Azitra investors own include NVIDIA (NVDA), Broadcom (AVGO), Tesla (TSLA), Advanced Micro Devices (AMD), CrowdStrike (CRWD), FedEx (FDX) and Intel (INTC). Company Calendar Last Earnings5/13/2026Today7/22/2026Next Earnings (Estimated)8/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 AZTR's financial health is in the Green zone, according to TradeSmith. AZTR has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNYSEAMERICAN:AZTR CIK1701478 Webazitrainc.com Phone203-646-6446FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Price Target for Azitra$4.00 High Price Target$4.00 Low Price Target$4.00 Potential Upside/Downside+2,953.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.95 million Net MarginsN/A Pretax MarginN/A Return on Equity-251.51% Return on Assets-185.99% Debt Debt-to-Equity RatioN/A Current Ratio6.94 Quick Ratio6.94 Sales & Book Value Annual Sales$10 thousand Price / Sales212.09 Cash FlowN/A Price / Cash FlowN/A Book Value$0.35 per share Price / Book0.37Miscellaneous Outstanding Shares16,190,000Free Float16,147,000Market Cap$2.12 million OptionableNot Optionable Beta-1.21 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NYSEAMERICAN:AZTR) was last updated on 7/22/2026 by MarketBeat.com Staff. From Our PartnersYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredElon says “don’t save money.” Is he right?Robert Kiyosaki, author of Rich Dad Poor Dad, says you don't have to wait for Elon Musk's vision of universal ...Freedom Financial | SponsoredMy next big call (under $1)17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...Crypto 101 Media | SponsoredTrump’s emergency dollar resetBloomberg research shows the U.S. dollar's share of global reserves has fallen to the lowest level this centur...Porter & Company | SponsoredAmerican’s Biggest Threat Is HereThis feels like one of those ''where were you when Kennedy was shot'' moments. It felt like a moment in time, ...Goldco Direct, LLC | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredWhat's the Best Way to Lower RMD Taxes?Once you turn 73, the IRS requires you to take distributions from your IRA, 401(k), and other retirement accou...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Azitra, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Azitra With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
